PatientsVille.com Logo

DECREASED APPETITE and Atenolol

PatientsVille

DECREASED APPETITE Symptoms and Causes

Pulmonary hypertension (PH) is high blood pressure in the arteries to your lungs. It is a serious condition. If you have it, the blood vessels that carry blood from your heart to your lungs become hard and narrow. Your heart has to work harder to pump the blood through. Over time, your heart weakens and cannot do its job and you can develop heart failure.

Symptoms of PH include

  • Shortness of breath during routine activity, such as climbing two flights of stairs
  • Tiredness
  • Chest pain
  • A racing heartbeat
  • Pain on the upper right side of the abdomen
  • Decreased appetite

As PH worsens, you may find it hard to do any physical activities.

There are two main kinds of PH. One runs in families or appears for no known reason. The other kind is related to another condition, usually heart or lung disease.

There is no cure for PH. Treatments can control symptoms. They involve treating the heart or lung disease, medicines, oxygen, and sometimes lung transplantation.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for DECREASED APPETITE

DECREASED APPETITE treatment research studies

Atenolol clinical trials, surveys and public health registries


Find Drug Side Effect reports



Atenolol Side Effects

Bradycardia (333)
Dizziness (236)
Hypotension (218)
Completed Suicide (205)
Dyspnoea (180)
Nausea (171)
Blood Pressure Increased (150)
Syncope (145)
Hypertension (141)
Asthenia (141)
Fatigue (124)
Diarrhoea (124)
Headache (118)
Pain (115)
Malaise (110)
Toxicity To Various Agents (108)
Chest Pain (107)
Fall (98)
Palpitations (93)
Cerebrovascular Accident (89)
Vomiting (87)
Insomnia (81)
Myocardial Infarction (79)
Anxiety (78)
Oedema Peripheral (76)
Off Label Use (75)
Depression (75)
Pruritus (74)
Feeling Abnormal (73)
Back Pain (69)
Pain In Extremity (67)
Renal Failure Acute (66)
Abdominal Pain (66)
Arthralgia (66)
Weight Decreased (63)
Cough (62)
Heart Rate Increased (58)
Muscle Spasms (58)
Rash (58)
Blood Creatinine Increased (57)
Pneumonia (54)
Hyperkalaemia (54)
Loss Of Consciousness (53)
Overdose (53)
Weight Increased (53)
Hyperhidrosis (52)
Blood Cholesterol Increased (51)
Heart Rate Decreased (50)
Renal Failure (50)
Somnolence (50)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

8-)Have been taking atenolol and lisinipril for about 6 years, and before now did not realize the extreme itchiness in toes and fingers that started at first and now has turned in very cold and numb toes and feet and getting worse. I now believe it

Anxiety, Paranoia, Arrythmia

Before I took atenolol i had a perfect glucose numbers after taking it I came down with diabetes. I am 102lbs, 4'11, have always eaten healthy, exercise my whole life. I am 76. I was taken off atenolol after5 years...and NO ONE in my family for ge

Buenas quisiera saber si venden el medicamento rapamude o sirolimus en jarabe de 120 ml quisiera saber el costo,espero pronta respuesta muchas gracias

Congested chest

Has anyone else suffered from Atenelol induced Asthama and Bronchitis?

I have certain days of fatigue and I have constant chest congestion. How much can be attributed to the Atenolol or to my medical condition (atrial fibrulation)--I do not know.

I was started on atenolol for anxiety to stop the adrenilin, my bp was just a little elevated 150-100 during paniac attack. Will this drug work for anxiety?

I was told by increasing Atenol to 100 mg the pos. side effect was it protected your eyes from diabetes is this true on Your Mind?

It is the worst drug ever made made meel feel like been run over

1st day was hell, had about every side effect in the book. 2nd day was better, side effects decreased greatly 5th day is going well so far- feeling a little 'edgy & apprehensive' but better than the alternative

40mg per dose 3 days a week Nausea and tiredness and fatigue and loss of appetite 30 mg - doing better But has anyone else experienced a sore tender neck with radiating sore ear jaw and headache

Afater taking glifage for 5 months, stopped because of complete lack of appetite and taste, loss of 20 lbs. and thinking process affected.

After 1 day I developed sevre flu-like body aches and total loss of appetite. It was 4 days before I remembered to read the side effect fact sheet and realized what this drug was putting me through. I had shortness of breath wnen I tried to

After a few weeks on Piascledine, knee and back pain decreased considerably with no side effects noted. Not perfect, but much better. I was walking like an old man.

After a nasty experience with citalapram i was advised by my doc to try mirtazapine and it has suitedme very well. only side effect i canreport is an appetite increase. However as i don't carry much weight that isnt a problem.&

After dealing with nausea for days, total lack of appetite I then started with a temp.of 101.5 and it went up to 103. That lasted for 3 days ( my sinuss infection at this point was cleard up, so I stopped taking the meds. NOW, I am experiencing very

After having stilnoct for atleast 6 months, there is occuring of head heaviness,fever, dry mouth,constipation, lack of appetite.

Age 79, sciatic, pain relief with 2 to 3 per day. slight loss of appetite

Am on Klacid, two tablets daily. Experiencing increase in heart rate, Chest pains, Bitter taste in the mouth day and night; also everything tastes bitter, Lack of appetite, stomach ache, abdominal pains,stomach bloated; tired yet anxious. Sleepless n

DECREASED APPETITE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.
Condition: Chronic Stable Angina
Interventions: Drug: Nicorandil;   Drug: Atenolol
Outcome Measures: SPECT Tc99m- Tetrofosmin (MYOVIEW);   Exercise ECG Testing - Bruce protocol
2 Recruiting Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol
Condition: Marfan Syndrome
Interventions: Drug: Aliskiren;   Drug: Atenolol
Outcome Measures: Central aortic PWV(pulsed wave velocity);   Central aortic distensibility by MRI at week 24
3 Recruiting A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function
Condition: Hypertension
Interventions: Drug: Nebivolol;   Drug: Atenolol;   Drug: placebo
Outcome Measures: Comparing effects of nebivolol against Atenolol and placebo on endothelial function;   Evaluate effects of nebivolol as compared to Atenolol and placebo
4 Recruiting Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
Condition: Atrial Fibrillation
Intervention: Drug: Atenolol
Outcome Measure: Ventricular rate response during exercise.
5 Recruiting Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
Condition: Hypertension
Interventions: Drug: Fimasartan;   Drug: Atenolol
Outcome Measures: The difference of sitting Systolic Blood Pressure(SiSBP) between at the peak compared to at resting;   The difference of sitting Diastolic Blood Pressure(SiDBP) at the peak compared to at resting;   The difference of sitting Systolic Blood Pressure(SiSBP) at each exercising stage compared to at resting;   The difference of sitting Systolic Blood Pressure(SiSBP) among at resting, each exercising stage and recovery
6 Recruiting Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol
Conditions: Hypertension;   Metabolic Syndrome
Interventions: Drug: Atenolol;   Drug: Bisoprolol
Outcome Measures: central blood pressure;   peripheral resistance;   cardiac index;   pulse wave velocity
7 Recruiting Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)
Condition: Cardiac Disease
Interventions: Drug: Atenolol;   Drug: Telmisartan
Outcome Measures: Change from baseline in ascending aorta size, as evaluated by MRI;   Rate of change in ascending aorta size evaluated by transthoracic echocardiography (TEE).
8 Unknown  Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Atenolol
Outcome Measures: Change in diastolic function (annular tissue velocity [Em]);   Change in free fatty acid kinetics;   Change in insulin sensitivity, glucose effectiveness, glucose, insulin, high-density lipoprotein (HDL), or triglycerides
9 Unknown  A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
Condition: Marfan Syndrome
Interventions: Drug: Losartan and Atenolol or Propranolol;   Drug: Atenolol or Propranolol
Outcome Measure: Echocardiograms
10 Recruiting Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
Condition: Healthy
Interventions: Drug: Saline;   Drug: Glucagon;   Drug: Placebo;   Drug: Atenolol
Outcome Measures: Circulating acyl-ghrelin concentration after glucagon stimulation with and without beta-adrenergic blockade;   Association between circulating acyl-ghrelin concentration and GH and cortisol after glucagon administration with and without beta-adrenergic blockade
11 Recruiting Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
Condition: Hypertension
Intervention: Drug: Lisinopril, Atenolol
Outcome Measure: One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
12 Recruiting Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm
Condition: Small Abdominal Aortic Aneurysm
Interventions: Drug: Beta-blocker-Atenolol 50mg, PO(peroral), Once daily;   Drug: Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily
Outcome Measure: Annual aneurysm growth of abdominal aortic aneurysm
13 Not yet recruiting Single Pill to Avert Cardiovascular Events
Condition: Cardiovascular Disease
Interventions: Drug: polipillV1;   Drug: polipillV2;   Drug: usual care
Outcome Measures: compliance with treatment;   changed in blood pressure;   changes in LDL-cholesterol levels;   the main reason for non compliance with treatment;   safety of poli pill measures by laboratorial tests;   combined outcome
14 Recruiting Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Cardiovascular Risk Assessment
Conditions: Essential Hypertension;   Cardiovascular Disease;   Stroke;   Chronic Kidney Disease
Interventions: Drug: Any antihypertensive medication alone or in combination;   Device: Ambulatory blood pressure monitoring
Outcome Measures: To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular and renal risk assessment.;   To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.;   To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.;   To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of white-coat hypertension.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of masked hypertension.;   To evaluate, for all previous objectives, potential differences between men and women.;   To evaluate the impact of changes in ambulatory BP in cardiovascular, cerebrovascular and renal risk assessment.
15 Recruiting Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF
Condition: Atrial Fibrillation
Intervention: Other: Aggressive Blood Pressure control
Outcome Measures: Time to recurrent Atrial fibrillation;   Recurrence of AF at one year
16 Unknown  Heart Rate Reduction in Heart Failure
Condition: Heart Failure
Interventions: Drug: ivabradine;   Drug: Carvedilol/Ivabradine;   Drug: Carvedilol
Outcome Measures: Exercise tolerance assessed by 6 minute walking test;   Quality of life
17 Unknown  Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study
Conditions: Hypertension;   Diabetes;   Death From Cardiovascular Disease;   Myocardial Infarction;   Stroke
Intervention:
Outcome Measures: Number of participants who have died from cardiovascular disease and the number who have suffered a non-fatal myocardial infarction (MI) and/or non-fatal stroke since the end of the ASCOT study;   Number of participants who have developed diabetes since the end of the ASCOT trial;   Number of participants who have undergone coronary/peripheral re-vascularisation procedures since the end of the ASCOT trial;   Number of participants who have required renal replacement therapy (dialysis or kidney transplant) since the end of the ASCOT trial;   Number of participants who have experienced a transient ischaemic attack since the end of the ASCOT trial
18 Recruiting The International Polycap Study 3 (TIPS-3)
Conditions: Cardiovascular Disease;   Fractures;   Cancers
Interventions: Drug: Polycap DS;   Drug: enteric coated aspirin;   Drug: cholecalciferol
Outcome Measures: Composite of major CVD (CV death, non-fatal stroke, non-fatal MI), plus heart failure, resuscitated cardiac arrest, or revascularization with evidence of ischemia in participants taking Polycap versus placebo;   Composite of CV events (CV death, MI or stroke) and cancer in participants taking aspirin versus placebo;   Risk of fractures in participants taking vitamin D versus placebo;   Composite of CV death, non-fatal stroke, and nonfatal MI in participants taking Polycap versus placebo;   Composite outcome of CV events and cancers after 10 years of follow up in participants taking aspirin versus placebo;   Composite outcome of CV events, fractures and cancers, and the risk of the falls at 10 years of follow up in participants taking vitamin D versus placebo
19 Recruiting Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Conditions: Atrial Fibrillation;   Arrhythmia
Interventions: Device: Left atrial ablation;   Drug: Rate or Rhythm Control Therapy
Outcome Measures: LA catheter ablation is superior to rate or rhythm control drug therapy for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients warranting therapy for AF.;   LA catheter ablation is superior to rate or rhythm control drug therapy for reducing total mortality;   Total mortality or cardiovascular hospitalization;   Cardiovascular death;   Cardiovascular death or disabling stroke;   Arrhythmic death or cardiac arrest;   Heart failure death;   Freedom from recurrent AF;   Cardiovascular hospitalization;   Medical costs, resource utilization, and cost effectiveness;   Quality of Life;   Composite adverse events;   Left atrial size, morphology and function and its relationship to morbidity and mortality